Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study)

Fumio Imamura, Makoto Nishio, Rintaro Noro, Masahiro Tsuboi, Norihiko Ikeda, Akira Inoue, Yoshinobu Ohsaki, Yukio Kimura, Kazumi Nishino, Junji Uchida, Takeshi Horai

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)

Abstract

Background: Gemcitabine combined with carboplatin (CG) is one of the regimens used widely for advanced non-small cell lung cancer. Improvement in its toxicity may result in good clinical outcomes. Methods: A new schedule of gemcitabine and carboplatin (CG8) was compared with the standard one (CG1). Both are 3-weekly regimens, but carboplatin is administered on day 1 in CG1 and on day 8 in CG8. Results: The response rate of CG1 was 29.2%, which was higher than that of CG8 (22.2%). Median survival times in CG1 and CG8 were 348 and 455.5 days, respectively. Grade ≥3 leukopenia, thrombocytopenia and anemia were observed in 56.0, 72.0 and 36.0% of patients with CG1 and in 33.3, 25.9 and 14.8% of patients with CG8, respectively. Whereas grade ≥3 elevation of asparatate aminotransferase, alanine aminotransferase and alkaline phosphatase was seen mainly in CG8, grade ≥3 non-hematologic toxicities such as febrile neutropenia, infection, appetite loss, diarrhea and eruption were observed only in CG1. Conclusion: CG1 is superior in response rate, but CG8 shows improved toxicities and a tendency of prolonged survival.

Original languageEnglish
Pages (from-to)357-362
Number of pages6
JournalChemotherapy
Volume57
Issue number4
DOIs
Publication statusPublished - 2011 Sep

Keywords

  • Carboplatin
  • Gemcitabine
  • Lung cancer
  • Randomized phase II study
  • Thrombocytopenia

ASJC Scopus subject areas

  • Oncology
  • Pharmacology
  • Drug Discovery
  • Pharmacology (medical)
  • Infectious Diseases

Fingerprint

Dive into the research topics of 'Randomized phase II study of two schedules of carboplatin and gemcitabine for stage IIIB and IV advanced non-small cell lung cancer (JACCRO LC-01 study)'. Together they form a unique fingerprint.

Cite this